31 results on '"Cong, Mian-er"'
Search Results
2. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
- Author
-
Radzio-Basu, Jessica, Council, Olivia, Cong, Mian-er, Ruone, Susan, Newton, Alicia, Wei, Xierong, Mitchell, James, Ellis, Shanon, Petropoulos, Christos J., Huang, Wei, Spreen, William, Heneine, Walid, and García-Lerma, J. Gerardo
- Published
- 2019
- Full Text
- View/download PDF
3. Prophylactic Efficacy of Oral Emtricitabine and Tenofovir Disoproxil Fumarate Combination Therapy Against a Tenofovir-Resistant Simian/Human Immunodeficiency Virus Containing the K65R Mutation in Macaques
- Author
-
Cong, Mian-er, Mitchell, James, Sweeney, Elizabeth, Bachman, Shanon, Hanson, Debra L., Heneine, Walid, and García-Lerma, J. Gerardo
- Published
- 2013
- Full Text
- View/download PDF
4. Reduced Inflammation and CD4 Loss in Acute SHIV Infection During Oral Pre-Exposure Prophylaxis
- Author
-
Kersh, Ellen N., Luo, Wei, Zheng, Qi, Adams, Debra R., Hanson, Debra, Youngpairoj, Ae S., Cong, Mian-er, Butler, Katherine, Hendry, R. Michael, McNicholl, Janet M., Heneine, Walid, and Garcia-Lerma, J. Gerardo
- Published
- 2012
- Full Text
- View/download PDF
5. On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors
- Author
-
Kuklenyik, Zsuzsanna, Martin, Amy, Pau, Chou-Pong, Holder, Angela, Youngpairoj, Ae S., Zheng, Qi, Cong, Mian-Er, Garcia-Lerma, J. Gerardo, Heneine, Walid, Pirkle, James L., and Barr, John R.
- Published
- 2009
- Full Text
- View/download PDF
6. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir
- Author
-
Garcia-Lerma, J. Gerardo, Otten, Ron A., Qari, Shoukat H., Jackson, Eddie, Cong, Mian-er, Masciotra, Silvina, Luo, Wei, Kim, Caryn, Adams, Debra R., Monsour, Michael, Lipscomb, Jonathan, Johnson, Jeffrey A., Delinsky, David, Schinazi, Raymond F., Janssen, Robert, Folks, Thomas M., and Heneine, Walid
- Subjects
Biological sciences - Abstract
Background In the absence of an effective vaccine, HIV continues to spread globally, emphasizing the need for novel strategies to limit its transmission. Pre-exposure prophylaxis (PrEP) with antiretroviral drugs could prove to be an effective intervention strategy if highly efficacious and cost-effective PrEP modalities are identified. We evaluated daily and intermittent PrEP regimens of increasing antiviral activity in a macaque model that closely resembles human transmission. Methods and Findings We used a repeat-exposure macaque model with 14 weekly rectal virus challenges. Three drug treatments were given once daily, each to a different group of six rhesus macaques. Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC), group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose of tenofovir. A fourth group of six rhesus macaques (group 4) received intermittently a PrEP regimen similar to group 3 only 2 h before and 24 h after each weekly virus challenge. Results were compared to 18 control macaques that did not receive any drug treatment. The risk of infection in macaques treated in groups 1 and 2 was 3.8- and 7.8-fold lower than in untreated macaques (p = 0.02 and p = 0.008, respectively). All six macaques in group 3 were protected. Breakthrough infections had blunted acute viremias; drug resistance was seen in two of six animals. All six animals in group 4 that received intermittent PrEP were protected. Conclusions This model suggests that single drugs for daily PrEP can be protective but a combination of antiretroviral drugs may be required to increase the level of protection. Short but potent intermittent PrEP can provide protection comparable to that of daily PrEP in this SHIV/macaque model. These findings support PrEP trials for HIV prevention in humans and identify promising PrEP modalities., Introduction With an estimated 33.2 million people worldwide living with HIV at the end of 2007 and an estimated 2.5 million new infections in 2007 acquired mostly through sex, HIV/AIDS [...]
- Published
- 2008
7. Ancient co-speciation of simian foamy viruses and primates
- Author
-
Switzer, William M., Salemi, Marco, Shanmugam, Vedapuri, Gao, Feng, Cong, Mian-er, Kuiken, Carla, Bhullar, Vinod, Beer, Brigitte E., Vallet, Dominique, Gautier-Hion, Annie, Tooze, Zena, Villinger, Francois, Holmes, Edward C., and Heneine, Walid
- Subjects
Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
Author(s): William M. Switzer (corresponding author) [1]; Marco Salemi [2]; Vedapuri Shanmugam [1]; Feng Gao [3]; Mian-er Cong [1]; Carla Kuiken [4]; Vinod Bhullar [1]; Brigitte E. Beer [5]; Dominique [...]
- Published
- 2005
- Full Text
- View/download PDF
8. LACK OF PROTECTION AGAINST RECTAL SHIV TRANSMISSION BY PROPHYLACTIC TREATMENT WITH GS7340 DESPITE HIGH RECTAL AND SYSTEMIC TENOFOVIR EXPOSURE: Abstract #53
- Author
-
Aung, Wutyi, Cong, Mian-er, Zheng, Qi, Youngpairoj, Ae, Holder, Angela, Luo, Wei, Mitchell, James, Hanson, Debra, Kersh, Ellen, Pau, Chou-Pong, Ray, Adrian, Rooney, Jim, Lee, Bill, Heneine, Walid, and Gerardo Garcia-Lerma, & J.
- Published
- 2011
9. ASSESSING DRUG RESISTANCE EMERGENCE IN A MACAQUE MODEL OF ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS (PREP): Abstract #54
- Author
-
Dobard, Charles, Masciotra, Silvina, Lipscomb, Jonathan, Youngpairoj, Ae, Cong, Mian-er, Sharma, Sunita, Johnson, Jeffrey, Garcia-Lerma, Gerardo, and Heneine, & Walid
- Published
- 2011
10. Prevention of rectal SHIV transmission in macaques by intermittent pre-exposure prophylaxis (iPrEP) with oral Truvada: 003
- Author
-
Garcia-Lerma, Gerardo J., Cong, Mian-Er, Mitchell, James, Masciotra, Silvina, Youngpairoj, Ae S., Pau, Chou-Pong, Hanson, Debra, Otten, Ron, Paxton, Lynn, Folks, Thomas M., and Heneine, Walid
- Published
- 2009
11. Related TT Viruses in Chimpanzees
- Author
-
Cong, Mian-er, Nichols, Barbara, Dou, Xiao-guang, Spelbring, John E., Krawczynski, Krzysztof, Fields, Howard A., and Khudyakov, Yury E.
- Published
- 2000
- Full Text
- View/download PDF
12. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
- Author
-
Massud, Ivana, Cong, Mian-Er, Ruone, Susan, Holder, Angela, Dinh, Chuong, Nishiura, Kenji, Khalil, George, Pan, Yi, Lipscomb, Jonathan, Johnson, Ryan, Deyounks, Frank, Rooney, James F, Babusis, Darius, Park, Yeojin, McCallister, Scott, Callebaut, Christian, Heneine, Walid, and García-Lerma, J Gerardo
- Subjects
- *
HIV infections , *SIMIAN immunodeficiency virus , *MACAQUES , *TENOFOVIR , *HIV - Abstract
Background: Tenofovir alafenamide (TAF)-based regimens are being evaluated for pre-exposure prophylaxis (PrEP). We used a macaque model of repeated exposures to simian human immunodeficiency virus (SHIV) to investigate whether TAF alone or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection.Methods: Pigtail macaques were exposed vaginally to SHIV162p3 once a week for up to 15 weeks. Animals received clinical doses of FTC/TAF (n = 6) or TAF (n = 9) orally 24 hours before and 2 hours after each weekly virus exposure. Infection was compared with 21 untreated controls.Results: Five of the 6 animals in the FTC/TAF and 4 of the 9 animals in the TAF alone group were protected against infection (P = .001 and P = .049, respectively). The calculated efficacy of FTC/TAF and TAF was 91% (95% confidence interval [CI], 34.9%-98.8%) and 57.8% (95% CI, -8.7% to 83.6%), respectively. Infection in FTC/TAF but not TAF-treated macaques was delayed relative to controls (P = .005 and P = .114). Median tenofovir diphosphate (TFV-DP) levels in peripheral blood mononuclear cells (PBMCs) were similar among infected and uninfected macaques receiving TAF PrEP (351 and 143 fmols/106 cells, respectively; P = .921).Conclusions: Emtricitabine/TAF provided a level of protection against vaginal challenge similar to FTC/TFV disoproxil fumarate combination in the macaque model. Our results support the clinical evaluation of FTC/TAF for PrEP in women. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. Sequence Heterogeneity within Three Different Regions of the Hepatitis G Virus Genome
- Author
-
Cong, Mian-er, Fried, Michael W., Lambert, Stephen, Lopareva, Elena N., Zhan, Meiyun, Pujol, Flor H., Thyagarajan, S.P., Byun, Kwan Soo, Fields, Howard A., and Khudyakov, Yury E.
- Published
- 1999
- Full Text
- View/download PDF
14. Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs.
- Author
-
Cong, Mian-er, Pau, Chou-Pong, Heneine, Walid, and García-Lerma, J. Gerardo
- Subjects
- *
HIV prevention , *EMTRICITABINE-tenofovir , *ANTIRETROVIRAL agents , *PATIENT compliance , *LYMPHOID tissue , *LABORATORY monkeys - Abstract
Background: Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) is a novel HIV prevention strategy. Suboptimal PrEP adherence and HIV infection creates an opportunity for continued antiretroviral drug activity during undiagnosed infection. We previously showed that macaques infected with SHIV during PrEP with FTC/TDF display reduced acute plasma viremias and limited virus diversity. We investigated the effect of PrEP on acute SHIV DNA dynamics and on the size of the persistent virus reservoir in lymphoid tissues. Design: Cell-associated SHIV DNA levels in PBMCs were measured in 8 macaques infected during PrEP with FTC/TDF or single-agent TAF and was compared to those seen in untreated infections (n = 10). PrEP breakthrough infections continued treatment with 1–2 weekly drug doses to model suboptimal drug exposure during undiagnosed HIV infection in humans. SHIV DNA was also measured in lymphoid tissues collected from FTC/TDF PrEP breakthroughs after 1 year of infection. Results: Compared to untreated controls, PrEP infections had reduced plasma RNA viremias both at peak and throughout weeks 1–12 (p<0.005). SHIV DNA levels were also reduced at peak and during the first 12 weeks of infection (p<0.043) but not throughout weeks 12–20. At 1 year, SHIV DNA reservoirs in lymphoid tissues were similar in size among macaques that received PrEP or placebo. Conclusions: Antiviral drug activity due to PrEP limits acute SHIV replication but has only a transient effect on cell-associated SHIV DNA levels. Our model suggests that suboptimal drug exposure in persons that are taking PrEP and become infected with HIV may not be sufficient to reduce the pool of HIV-infected cells, and that treatment intensification may be needed to sustain potential virological benefits from the PrEP regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
- Author
-
Dobard, Charles W., Sharma, Sunita, Cong, Mian-er, West, Rolieria, Makarova, Natalia, Holder, Angela, Chou-Pong Pau, Hanson, Debra L., Novembre, Francis J., Garcia-Lerma, Jose Gerardo, and Heneine, Walid
- Subjects
HIV prevention ,TENOFOVIR ,MACAQUES ,GENETIC mutation ,PYROPHOSPHATES ,DISEASES ,THERAPEUTICS - Abstract
Background: Topically delivered tenofovir (TFV) from intravaginal rings, tablets, or gels is being evaluated for HIV prevention. We previously demonstrated that TFV delivered vaginally by gel protected macaques from vaginal infection with SHIV. Here we investigated efficacy of the TFV gel against vaginal transmission of a TFV-resistant SHIV containing the K65R mutation (SHIV162P3
K65R ) and its relationship to drug levels in vaginal tissues. Results: SHIV162P3K65R shows approximately a 5-fold reduction in susceptibility to TFV compared to wild-type SHIV. Efficacy was evaluated in pig-tailed macaques exposed vaginally twice-weekly (up to 10 weeks) to SHIV162P3K65R 30 min after receiving placebo (n = 6) or 1% TFV (n = 6) gel. Four of the six controls were infected after a median of 5 exposures. In contrast, five of six macaques that received TFV gel remained uninfected after 20 vaginal SHIV162P3K65R exposures, resulting in an estimated efficacy of 75%. The mean intracellular TFV-diphosphate (TFV-DP) concentrations in vaginal lymphocytes 4 h after a single gel dose were found to be high (1,631 fmol/106 cells, range 492-3,847) and within the in vitro IC75 range (1,206 fmol/106 cells) for SHIV162P3K65R . Conclusion: Both the modest resistance conferred by K65R and the high TFV-DP exposure in vaginal lymphocytes, likely explain the observed protection. The findings in this model do not predict complete loss of protection by topical TFV against vaginal exposure to HIV-1K65R viruses and provide a tissue drug target for high efficacy. These data will facilitate the development of TFV delivery platforms that have high activity on both wild-type and TFV-resistant viruses. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
16. Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis.
- Author
-
Curtis, Kelly A, Kennedy, M Susan, Luckay, Amara, Cong, Mian-er, Youngpairoj, Ae S, Zheng, Qi, Smith, James, Hanson, Debra, Heneine, Walid, Owen, S Michele, and García-Lerma, J Gerardo
- Published
- 2011
- Full Text
- View/download PDF
17. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques
- Author
-
Cong, Mian-er, Youngpairoj, Ae S., Aung, Wutyi, Sharma, Sunita, Mitchell, James, Dobard, Charles, Heneine, Walid, and Garcia-Lerma, J. Gerardo
- Subjects
- *
DRUG resistance , *HIV , *EMTRICITABINE , *TENOFOVIR , *INFECTIOUS disease transmission , *MACAQUES , *VIRION - Abstract
Abstract: Transmission of drug-resistant HIV has been widely documented. We generated tenofovir (TFV)- and emtricitabine (FTC)-resistant SHIV162P3 mutants that can be used to investigate the transmission efficiency of drug-resistant viruses and their impact on the efficacy of pre-exposure prophylaxis. Both SHIV162p3M184V and SHIV162p3K65R replicated in vitro at high titers. Drug resistance profiles were similar to those seen in HIV. Virus infectivity to virion particle ratios were 4- and 10-fold lower in SHIV162p3M184V and SHIV162p3K65R, compared to a concurrently generated WT SHIV162p3, respectively. Mucosal transmissibility studies using a repeat low-dose macaque model of rectal and vaginal transmission showed that both mutants were able to efficiently infect macaques only after the dose was increased to adjust for fitness reductions due to K65R and M184V. Our results in limited number of macaques suggest that the reduction in fitness due to M184V and K65R decreases virus transmissibility, and identify in vitro infectivity parameters that associate with mucosal transmissibility. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
18. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection.
- Author
-
García-Lerma, J. Gerardo, Cong, Mian-er, Mitchell, James, Youngpairoj, Ae S., Zheng, Qi, Masciotra, Silvina, Martin, Amy, Kuklenyik, Zsuzsanna, Holder, Angela, Lipscomb, Jonathan, Chou-Pong Pau, Barr, John R., Hanson, Debra L., Otten, Ron, Paxton, Lynn, Folks, Thomas M., and Heneine, Walid
- Published
- 2010
- Full Text
- View/download PDF
19. Primary structure of open reading frame 2 and 3 of the hepatitis E virus isolated from Morocco.
- Author
-
Meng, Jihong, Cong, Mian-er, Dai, Xing, Pillot, Jacques, Purdy, Michael A., Fields, Howard A., and Khudyakov, Yury E.
- Published
- 1999
- Full Text
- View/download PDF
20. Natural resistance of human immunodeficiency virus type 2 to zidovudine
- Author
-
Reid, Patrick, MacInnes, Hamish, Cong, Mian-er, Heneine, Walid, and Gerardo García-Lerma, J.
- Subjects
- *
HIV , *HTLV , *HIV antibodies , *VIRAL load - Abstract
Abstract: Zidovudine (AZT) is a reverse transcriptase (RT) inhibitor widely used to treat persons infected with HIV-1 and HIV-2. Recent data on treated patients suggest differences in the antiviral activity of AZT between HIV-1 and HIV-2. We evaluated the antiviral activity of AZT on HIV-2 by using multiple approaches including in vitro selection experiments, analysis of growth kinetics with AZT, and phenotypic testing. A total of 5 wild-type (WT) HIV-2 viruses were used in the analysis. For comparison, 4 control WT HIV-1 strains and one HIV-1 mutant carrying the 215S mutation were evaluated in parallel. All 5 HIV-1 isolates acquired AZT resistance mutations after 3–6 passages with AZT or a 4- to 32-fold increase in AZT concentration. Among these viruses, the fastest selection of resistance was seen in HIV-1S215, which acquired S215Y (1-nucleotide change only) at passage 3 after only 17 days in culture. In contrast, none of the 5 HIV-2 viruses that naturally have S215 acquired S215Y/F or any other RT mutation during 10 passages with AZT (1025-fold increase in AZT concentration). In the presence of AZT + didanosine (ddI), 3 of the 5 HIV-1 isolates acquired AZT or ddI resistance mutations, while only ddI resistance mutations were seen in HIV-2 (4 of 5 isolates). All HIV-2 viruses replicated efficiently in high AZT concentrations and were about 200-fold less sensitive to AZT than HIV-1. In contrast, HIV-2 and HIV-1 were equally susceptible to ddI, a finding consistent with the selection of HIV-2 mutants with AZT + ddI. Our results demonstrate that the activity of AZT on HIV-2 is lower than previously thought, and emphasize the need for novel antiretroviral drugs specific for HIV-2. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
21. Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine.
- Author
-
Parikh, Urvi M., Dobard, Charles, Sharma, Sunita, Cong, Mian-Er, Hongwei Jia, Martin, Amy, Chou-Pong Pau, Hanson, Debra L., Guenthner, Patricia, Smith, James, Kersh, Ellen, Garcia-Lerma, J. Gerardo, Novembre, Francis J., Otten, Ron, Folks, Thomas, and Heneine, Walid
- Subjects
- *
HIV prevention , *ANTISEPTICS , *ANIMAL models in research , *MACAQUES , *T cells , *THERAPEUTICS - Abstract
New-generation gels that deliver potent antiretroviral drugs against human immunodeficiency virus type 1 have renewed hopes for topical prophylaxis as a prevention strategy. Previous preclinical research with monkey models suggested that high concentrations and drug combinations are needed for high efficacy. We evaluated two long-acting reverse transcriptase inhibitors, tenofovir (TFV) and emtricitabine (FTC), by using a twice-weekly repeat challenge macaque model and showed that a preexposure vaginal application of gel with 1% TFV alone or in combination with 5% FTC fully protected macaques from a total of 20 exposures to simian-human immunodeficiency virus SF162p3. FTC and TFV were detected in plasma 30 min after vaginal application, suggesting rapid absorption. FTC was detected more frequently than TFV and showed higher levels, reflecting the fivefold-higher concentration of this drug than of TFV. Two of 12 repeatedly exposed but protected macaques showed limited T-cell priming, which did not induce resistance to infection when macaques were rechallenged. Thus, single drugs with durable antiviral activity can provide highly effective topical prophylaxis and overcome the need for noncoital use or for drug combinations which are more complex and costly to formulate and approve. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
22. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
- Author
-
Massud I, Ruone S, Zlotorzynska M, Haaland R, Mills P, Cong ME, Kelley K, Johnson R, Holder A, Dinh C, Khalil G, Pan Y, Kelley CF, Sanchez T, Heneine W, and García-Lerma JG
- Subjects
- Adenine administration & dosage, Adenine pharmacokinetics, Administration, Oral, Animals, Cross-Sectional Studies, Drug Combinations, Emtricitabine pharmacokinetics, Humans, Macaca, Male, Patient Compliance psychology, Pre-Exposure Prophylaxis, Quinolones pharmacokinetics, Rectum chemistry, Surveys and Questionnaires, Tenofovir pharmacokinetics, Adenine analogs & derivatives, Emtricitabine administration & dosage, HIV Infections prevention & control, Homosexuality, Male psychology, Patient Compliance statistics & numerical data, Quinolones administration & dosage, Tenofovir administration & dosage
- Abstract
Background: Daily oral pre- or post-exposure prophylaxis (PrEP or PEP) is highly effective in preventing HIV infection. However, many people find it challenging to adhere to a daily oral regimen. Chemoprophylaxis with single oral doses of antiretroviral drugs taken before or after sex may better adapt to changing or unanticipated sexual practices and be a desirable alternative to daily PrEP or PEP. We investigated willingness to use a single oral pill before or after sex among men who have sex with men (MSM) and assessed the biological efficacy of a potent antiretroviral combination containing elvitegravir (EVG), emtricitabine (FTC), and tenofovir alafenamide (TAF)., Methods: Data on willingness to use single-dose PrEP or PEP were obtained from the 2017 cycle of the American Men's Internet Survey (AMIS), an annual online behavioral surveillance survey of MSM in the United States. Antiretroviral drug levels were measured in humans and macaques to define drug distribution in rectal tissue and identify clinically relevant doses for macaque modeling studies. The biological efficacy of a single dose of FTC/TAF/EVG as PrEP or PEP was investigated using a repeat-challenge macaque model of rectal HIV infection., Findings: Through pharmacokinetic assessment in humans and macaques we found that EVG penetrates and concentrates in rectal tissues supporting its addition to FTC/TAF to boost and extend chemoprophylactic activity. Efficacy estimates for a single oral dose given to macaques 4h before or 2h after SHIV exposure was 91•7%[35•7%-98•9%] and 100%, respectively, compared to 80•1%[13•9%-95•4%] and 64•6%[-19•4%-89•5%] when single doses were given 6 and 24h post challenge, respectively. A two-dose regimen at 24h and 48h after exposure was also protective [77•1%[1•7%-94•7%]., Interpretation: Informed by user willingness, human and macaque pharmacokinetic data, and preclinical efficacy we show that single-dose prophylaxis before or after sex is a promising HIV prevention strategy. Carefully designed clinical trials are needed to determine if any of these strategies will be effective in humans., Funding: Funded by CDC intramural funds, CDC contract HCVJCG2-2016-03948 (to CFK), and a grant from the MAC AIDS Fund and by the National Institutes of Health [P30AI050409] - the Emory Center for AIDS Research (to MZ and TS)., (Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
23. On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human Immunodeficiency Virus Infection.
- Author
-
Ke R, Cong ME, Li D, García-Lerma JG, and Perelson AS
- Subjects
- Animals, DNA, Viral analysis, Macaca mulatta, Models, Theoretical, RNA, Viral blood, Viral Load, Cell Death, HIV growth & development, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus growth & development, T-Lymphocytes virology
- Abstract
Progressive T cell depletion during chronic human immunodeficiency virus type 1 (HIV) infection is a key mechanism that leads to the development of AIDS. Recent studies have suggested that most T cells in the tissue die through pyroptosis triggered by abortive infection, i.e., infection of resting T cells in which HIV failed to complete reverse transcription. However, the contribution of abortive infection to T cell loss and how quickly abortively infected cells die in vivo , key parameters for a quantitative understanding of T cell population dynamics, are not clear. Here, we infected rhesus macaques with simian-human immunodeficiency viruses (SHIV) and followed the dynamics of both plasma SHIV RNA and total cell-associated SHIV DNA. Fitting mathematical models to the data, we estimate that upon infection a majority of CD4
+ T cells (approximately 65%, on average) become abortively infected and die at a relatively high rate of 0.27 day-1 (half-life, 2.6 days). This confirms the importance of abortive infection in driving T cell depletion. Further, we find evidence suggesting that an immune response may be restricting viral infection 1 to 3 weeks after infection. Our study serves as a step forward toward a quantitative understanding of the mechanisms driving T cell depletion during HIV infection. IMPORTANCE In HIV-infected patients, progressive CD4+ T cell loss ultimately leads to the development of AIDS. The mechanisms underlying this T cell loss are not clear. Recent experimental data suggest that the majority of CD4+ T cells in tissue die through abortive infection, where the accumulation of incomplete HIV transcripts triggers cell death. To investigate the role of abortive infection in driving CD4+ T cell loss in vivo , we infected macaques with simian-human immunodeficiency viruses (SHIV) and followed the viral kinetics of both plasma RNA and cell-associated DNA during infection. Fitting mathematical models, we estimated that a large fraction of infected cells dies through abortive infection and has a half-life of approximately 2.6 days. Our results provide the first in vivo quantitative estimates of parameters characterizing abortive infection and support the notion that abortive infection represents an important mechanism underlying progressive CD4+ T cell depletion in vivo ., (Copyright © 2017 American Society for Microbiology.)- Published
- 2017
- Full Text
- View/download PDF
24. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
- Author
-
Curtis KA, Kennedy MS, Luckay A, Cong ME, Youngpairoj AS, Zheng Q, Smith J, Hanson D, Heneine W, Owen SM, and García-Lerma JG
- Subjects
- Adenine administration & dosage, Adenine analogs & derivatives, Adenine therapeutic use, Administration, Oral, Animals, Anti-HIV Agents administration & dosage, Antibodies, Viral blood, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Drug Combinations, Emtricitabine, HIV, HIV Antibodies physiology, Human Immunodeficiency Virus Proteins immunology, Macaca mulatta, Organophosphonates administration & dosage, Organophosphonates therapeutic use, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus drug effects, Tenofovir, Viral Load, Anti-HIV Agents therapeutic use, Antibodies, Viral physiology, Antibody Affinity, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology
- Abstract
Background: Pre-exposure prophylaxis (PrEP) is a novel intervention strategy for the prevention HIV transmission. Because several clinical trials are at various stages of completion, it is important to understand the impact of PrEP treatment on the development of the immune response to HIV, particularly in individuals who exhibit breakthrough infections despite PrEP., Methods: A model of HIV infection, using rhesus macaques and the simian/human immunodeficiency virus (SHIV), was used to evaluate the effects of PrEP on the evolution of the humoral immune response. Time to seroconversion, neutralizing and binding antibody levels, and antibody avidity were measured in 12 rhesus macaques infected during daily or intermittent PrEP with FTC (emtricitabine) or Truvada (FTC/tenofovir combination) and compared with 11 untreated, simian HIV-infected controls., Results: Macaques that became infected while receiving PrEP exhibited significantly lower peak virus loads during acute infection as compared with untreated animals. Although the timing of seroconversion and SHIV binding and neutralizing antibody levels were not impacted by treatment, lower maturation rates of antibody avidity for anti-p27, gp120, gp160, and gp41 were observed., Conclusions: This study suggests that reduced virus loads associated with PrEP treatment have little impact on timing of seroconversion and neutralizing/binding antibody levels; however, maturation of antibody avidity was suppressed.
- Published
- 2011
- Full Text
- View/download PDF
25. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.
- Author
-
Cong ME, Youngpairoj AS, Zheng Q, Aung W, Mitchell J, Sweeney E, Hanson DL, Hendry RM, Dobard C, Heneine W, and García-Lerma JG
- Subjects
- Animals, Cell Line, Deoxycytidine pharmacology, Drug Combinations, Drug Resistance, Viral, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, HIV genetics, Humans, Macaca mulatta, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Immunodeficiency Virus genetics, Antiviral Agents pharmacology, Deoxycytidine analogs & derivatives, HIV drug effects, Mutation, Organophosphorus Compounds pharmacology, Simian Acquired Immunodeficiency Syndrome transmission, Simian Immunodeficiency Virus drug effects
- Abstract
Daily preexposure prophylaxis (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a novel HIV prevention strategy recently found to reduce HIV incidence among men who have sex with men. We used a macaque model of HIV transmission to investigate if Truvada maintains prophylactic efficacy against an FTC-resistant isolate containing the M184V mutation. Five macaques received a dose of Truvada 3 days before exposing them rectally to the simian/human immunodeficiency virus mutant SHIV162p3(M184V), followed by a second dose 2 h after exposure. Five untreated animals were used as controls. Virus exposures were done weekly for up to 14 weeks. Despite the high (>100-fold) level of FTC resistance conferred by M184V, all five treated animals were protected from infection, while the five untreated macaques were infected (P = 0.0008). Our results show that Truvada maintains high prophylactic efficacy against an FTC-resistant isolate. Increased susceptibility to tenofovir due to M184V and other factors, including residual antiviral activity by FTC and/or reduced virus fitness due to M184V, may all have contributed to the observed protection.
- Published
- 2011
- Full Text
- View/download PDF
26. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
- Author
-
García-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, and Heneine W
- Subjects
- Adenine administration & dosage, Adenine pharmacokinetics, Adenine therapeutic use, Animals, Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacokinetics, Chemoprevention, HIV Infections virology, HIV Reverse Transcriptase antagonists & inhibitors, HIV-1 drug effects, Humans, Lymphocytes metabolism, Lymphoid Tissue metabolism, Macaca, Organophosphonates administration & dosage, Organophosphonates pharmacokinetics, Prodrugs administration & dosage, Prodrugs pharmacokinetics, Rectum virology, Reverse Transcriptase Inhibitors administration & dosage, Reverse Transcriptase Inhibitors pharmacokinetics, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus drug effects, Substrate Specificity, Tenofovir, Adenine analogs & derivatives, Anti-HIV Agents therapeutic use, Deoxyadenine Nucleotides metabolism, HIV Infections prevention & control, Organophosphonates therapeutic use, Prodrugs therapeutic use, Reverse Transcriptase Inhibitors therapeutic use, Simian Acquired Immunodeficiency Syndrome prevention & control
- Abstract
Preexposure prophylaxis (PrEP) with antiretroviral drugs is a novel human immunodeficiency virus (HIV) prevention strategy. It is generally thought that high systemic and mucosal drug levels are sufficient for protection. We investigated whether GS7340, a next-generation tenofovir (TFV) prodrug that effectively delivers tenofovir diphosphate (TFV-DP) to lymphoid cells and tissues, could protect macaques against repeated weekly rectal simian-human immunodeficiency virus (SHIV) exposures. Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) were about 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained above 1,000 fmol/10(6) cells for as long as 7 days. TFV-DP accumulated in lymphoid and rectal tissues, with concentrations at 3 days exceeding 500 fmol/10(6) mononuclear cells. Despite high mucosal and systemic TFV levels, GS7340 was not protective. Since TFV-DP blocks reverse transcription by competing with the natural dATP substrate, we measured dATP contents in peripheral lymphocytes, lymphoid tissue, and rectal mononuclear cells. Compared to those in circulating lymphocytes and lymphoid tissue, rectal lymphocytes had 100-fold higher dATP concentrations and dATP/TFV-DP ratios, likely reflecting the activated status of the cells and suggesting that TFV-DP may be less active at the rectal mucosa. Our results identify dATP/TFV-DP ratios as a possible correlate of protection by TFV and suggest that natural substrate concentrations at the mucosa will likely modulate the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.
- Published
- 2011
- Full Text
- View/download PDF
27. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis.
- Author
-
Kersh EN, Adams DR, Youngpairoj AS, Luo W, Zheng Q, Cong ME, Aung W, Mitchell J, Otten R, Hendry RM, Heneine W, McNicholl J, and Garcia-Lerma JG
- Subjects
- Administration, Oral, Animals, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes pathology, CD4-Positive T-Lymphocytes virology, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes virology, Cell Differentiation drug effects, Cytokines biosynthesis, Deoxycytidine administration & dosage, Deoxycytidine pharmacology, Deoxycytidine therapeutic use, Drug Combinations, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Epitopes immunology, Macaca mulatta immunology, Macaca mulatta virology, Male, Mucous Membrane drug effects, Mucous Membrane immunology, Organophosphorus Compounds administration & dosage, Organophosphorus Compounds pharmacology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus drug effects, Deoxycytidine analogs & derivatives, Mucous Membrane virology, Organophosphorus Compounds therapeutic use, Simian Acquired Immunodeficiency Syndrome drug therapy, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Immunodeficiency Virus immunology, Vaccination
- Abstract
Pre-exposure prophylaxis (PrEP) with anti-viral drugs is currently in clinical trials for the prevention of HIV infection. Induction of adaptive immune responses to virus exposures during anti-viral drug administration, i.e., a "chemo-vaccination" effect, could contribute to PrEP efficacy. To study possible chemo-vaccination, we monitored humoral and cellular immune responses in nine rhesus macaques undergoing up to 14 weekly, low-dose SHIV(SF162P3) rectal exposures. Six macaques concurrently received PrEP with intermittent, oral Truvada; three were no-PrEP controls. PrEP protected 4 macaques from infection. Two of the four showed evidence of chemo-vaccination, because they developed anti-SHIV CD4(+) and CD8(+) T cells; SHIV-specific antibodies were not detected. Control macaques showed no anti-SHIV immune responses before infection. Chemo-vaccination-induced T cell responses were robust (up to 3,940 SFU/10(6) PBMCs), predominantly central memory cells, short-lived (≤22 weeks), and appeared intermittently and with changing specificities. The two chemo-vaccinated macaques were virus-challenged again after 28 weeks of rest, after T cell responses had waned. One macaque was not protected from infection. The other macaque concurrently received additional PrEP. It remained uninfected and T cell responses were boosted during the additional virus exposures. In summary, we document and characterize PrEP-induced T cell chemo-vaccination. Although not protective after subsiding in one macaque, chemo-vaccination-induced T cells warrant more comprehensive analysis during peak responses for their ability to prevent or to control infections after additional exposures. Our findings highlight the importance of monitoring these responses in clinical PrEP trials and suggest that a combination of vaccines and PrEP potentially might enhance efficacy.
- Published
- 2011
- Full Text
- View/download PDF
28. Clinical and virological characterization of persistent human infection with simian foamy viruses.
- Author
-
Boneva RS, Switzer WM, Spira TJ, Bhullar VB, Shanmugam V, Cong ME, Lam L, Heneine W, Folks TM, and Chapman LE
- Subjects
- Adult, Animals, Blood virology, DNA, Viral genetics, Family Health, Female, Humans, Interviews as Topic, Male, Middle Aged, Primates, Proviruses isolation & purification, Retroviridae Infections pathology, Saliva virology, Semen virology, Simian foamy virus isolation & purification, Urine virology, Retroviridae Infections physiopathology, Retroviridae Infections virology, Simian foamy virus genetics, Zoonoses virology
- Abstract
Persons occupationally exposed to nonhuman primates (NHPs) can be persistently infected with simian foamy virus (SFV). The clinical significance and person-to-person transmissibility of zoonotic SFV infection is unclear. Seven SFV-infected men responded to annual structured interviews and provided whole blood, oral, and urogenital specimens for study. Wives were tested for SFV infection. Proviral DNA was consistently detected by PCR in PBMCs of infected men and inconsistently in oral or urogenital samples. SFV was infrequently cultured from their PBMCs and throat swabs. Despite this and a long period of intimate exposure (median 20 years), wives were SFV negative. Most participants reported nonspecific symptoms and diseases common to aging. However, one of two persons with mild thrombocytopenia had clinically asymptomatic nonprogressive, monoclonal natural killer cell lymphocytosis of unclear relationship to SFV. All participants worked with NHPs before 1988 using mucocutaneous protection inconsistently; 57% described percutaneous injuries involving the infecting NHP species. SFV likely transmits to humans through both percutaneous and mucocutaneous exposures to NHP body fluids. Limited follow-up has not identified SFV-associated illness and secondary transmission among humans.
- Published
- 2007
- Full Text
- View/download PDF
29. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations.
- Author
-
Johnson JA, Li JF, Wei X, Lipscomb J, Bennett D, Brant A, Cong ME, Spira T, Shafer RW, and Heneine W
- Subjects
- Anti-HIV Agents pharmacology, Base Sequence, Cloning, Molecular, DNA Primers, Gene Amplification, HIV-1 classification, HIV-1 drug effects, Mutation, Oligodeoxyribonucleotides chemistry, Plasmids genetics, Polymorphism, Genetic, Reverse Transcriptase Polymerase Chain Reaction, Sensitivity and Specificity, Drug Resistance, Viral genetics, HIV-1 genetics, Polymerase Chain Reaction methods
- Abstract
Background: The success of antiretroviral therapy is known to be compromised by drug-resistant HIV-1 at frequencies detectable by conventional bulk sequencing. Currently, there is a need to assess the clinical consequences of low-frequency drug resistant variants occurring below the detection limit of conventional genotyping. Sensitive detection of drug-resistant subpopulations, however, requires simple and practical methods for routine testing., Methodology: We developed highly-sensitive and simple real-time PCR assays for nine key drug resistance mutations and show that these tests overcome substantial sequence heterogeneity in HIV-1 clinical specimens. We specifically used early wildtype virus samples from the pre-antiretroviral drug era to measure background reactivity and were able to define highly-specific screening cut-offs that are up to 67-fold more sensitive than conventional genotyping. We also demonstrate that sequencing the mutation-specific PCR products provided a direct and novel strategy to further detect and link associated resistance mutations, allowing easy identification of multi-drug-resistant variants. Resistance mutation associations revealed in mutation-specific amplicon sequences were verified by clonal sequencing., Significance: Combined, sensitive real-time PCR testing and mutation-specific amplicon sequencing provides a powerful and simple approach that allows for improved detection and evaluation of HIV-1 drug resistance mutations.
- Published
- 2007
- Full Text
- View/download PDF
30. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
- Author
-
Cong ME, Heneine W, and García-Lerma JG
- Subjects
- Base Sequence, Drug Resistance, Viral drug effects, HIV Infections transmission, HIV Infections virology, HIV-1 enzymology, HIV-1 physiology, Humans, Kinetics, Molecular Sequence Data, Virus Replication, Anti-HIV Agents pharmacology, Drug Resistance, Viral genetics, HIV Reverse Transcriptase genetics, HIV-1 drug effects, Mutation, Reverse Transcriptase Inhibitors pharmacology
- Abstract
It is generally accepted that the fitness cost of resistance mutations plays a role in the persistence of transmitted drug-resistant human immunodeficiency virus type 1 and that mutations that confer a high fitness cost are less able to persist in the absence of drug pressure. Here, we show that the fitness cost of reverse transcriptase (RT) mutations can vary within a 72-fold range. We also demonstrate that the fitness cost of M184V and K70R can be decreased or enhanced by other resistance mutations such as D67N and K219Q. We conclude that the persistence of transmitted RT mutants might range widely on the basis of fitness and that the modulation of fitness cost by mutational interactions will be a critical determinant of persistence.
- Published
- 2007
- Full Text
- View/download PDF
31. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates.
- Author
-
Switzer WM, Bhullar V, Shanmugam V, Cong ME, Parekh B, Lerche NW, Yee JL, Ely JJ, Boneva R, Chapman LE, Folks TM, and Heneine W
- Subjects
- Animals, Antibodies, Viral blood, Ape Diseases virology, DNA, Mitochondrial genetics, Female, Gene Products, gag genetics, Gorilla gorilla virology, Humans, Integrases genetics, Male, Molecular Sequence Data, Polymerase Chain Reaction, Retroviridae Infections transmission, Retroviridae Infections veterinary, Retroviridae Infections virology, Sequence Analysis, DNA, Spumavirus genetics, Spumavirus immunology, Zoonoses virology, Ape Diseases transmission, Occupational Exposure, Pan troglodytes virology, Retroviridae Infections epidemiology, Spumavirus isolation & purification, Zoonoses transmission
- Abstract
The recognition that AIDS originated as a zoonosis heightens public health concerns associated with human infection by simian retroviruses endemic in nonhuman primates (NHPs). These retroviruses include simian immunodeficiency virus (SIV), simian T-cell lymphotropic virus (STLV), simian type D retrovirus (SRV), and simian foamy virus (SFV). Although occasional infection with SIV, SRV, or SFV in persons occupationally exposed to NHPs has been reported, the characteristics and significance of these zoonotic infections are not fully defined. Surveillance for simian retroviruses at three research centers and two zoos identified no SIV, SRV, or STLV infection in 187 participants. However, 10 of 187 persons (5.3%) tested positive for SFV antibodies by Western blot (WB) analysis. Eight of the 10 were males, and 3 of the 10 worked at zoos. SFV integrase gene (int) and gag sequences were PCR amplified from the peripheral blood lymphocytes available from 9 of the 10 persons. Phylogenetic analysis showed SFV infection originating from chimpanzees (n = 8) and baboons (n = 1). SFV seropositivity for periods of 8 to 26 years (median, 22 years) was documented for six workers for whom archived serum samples were available, demonstrating long-standing SFV infection. All 10 persons reported general good health, and secondary transmission of SFV was not observed in three wives available for WB and PCR testing. Additional phylogenetic analysis of int and gag sequences provided the first direct evidence identifying the source chimpanzees of the SFV infection in two workers. This study documents more frequent infection with SFV than with other simian retroviruses in persons working with NHPs and provides important information on the natural history and species origin of these infections. Our data highlight the importance of studies to better define the public health implications of zoonotic SFV infections.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.